Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Hematologic Diseases 1

Interventions

fludarabine 12Cyclophosphamide 11Busulfan 8Mycophenolic Acid 6Dexamethasone 6fludarabine phosphate 5Whole-Body Irradiation 5Tacrolimus 5Melphalan 5Lenalidomide 5Granulocyte Colony-Stimulating Factor 4isatuximab 3Thiotepa 3Sirolimus 3Rituximab 3Methotrexate 3Cyclosporine 3Blood Specimen Collection 3Alemtuzumab 3pomalidomide 2pembrolizumab 2daratumumab 2Vorinostat 2Stem Cell Transplantation 2Platelet Transfusion 2Ondansetron 2Interviews as Topic 2Filgrastim 2Exercise 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Diseases × Ustekinumab × Clear all
NCT04572815 2026-01-02

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Active not recruiting
116 enrolled

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡